Clinical Trial: Efficacy and Safety of Idarubicin-TACE Sequentially Followed by FOLFOX Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Early Intrahepatic Recurrent Hepatocellular Carcinoma After Liver Transplantation (China)

Posted On: 2026-09-25

China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Idarubicin-TACE Sequentially Followed by FOLFOX Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Early Intrahepatic Recurrent Hepatocellular Carcinoma After Liver Transplantation'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133396

Registration Time: 2026/09/24

Type: Observational study

Primary Sponsor: Shulan (Hangzhou) Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339312

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and Safety of Idarubicin-TACE Sequentially Followed by FOLFOX Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Early Intrahepatic Recurrent Hepatocellular Carcinoma After Liver Transplantation (China)